 |
Pharmacyclics Announces Progress With Lead Product Xcytrin® for Brain Metastases
Jan 9, 2001
|
11.3 KB |
|
| |
Sunnyvale, CAJanuary 9, 2001 Pivotal Phase III Clinical Trial Over 90 Percent Enrolled; Independent Data Safety Monitoring Board Gives Trial Favorable Review; Commercial Drug Supply Established
Pharmacyclics, Inc. (Nasdaq: ...
|
|
Pharmacyclics Announces Preliminary Phase I Study Results of Antrin® Photoangioplasty for Coronary Artery Disease
Nov 14, 2000
|
12.4 KB |
|
| |
New Orleans, LANovember 14, 2000Phase I Study of Antrin® Photoangioplasty for Peripheral Arterial Disease
Published in Circulation
PRNewswire -- Pharmacyclics, Inc.
(Nasdaq: PCYC)
today announced that pr...
|
|
Pharmacyclics Reports First Quarter Results
Nov 2, 2000
|
12.0 KB |
|
| |
Sunnyvale, CANovember 2, 2000PRNewswire --
Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its
first quarter ended September 30, 2000. The net loss for the period was
$8,215,000, or $0.51 per share, ...
|
|
Pharmacyclics Reports Promising Results From Lead-In Phase of Ongoing Phase III Trial of Xcytrin® for Brain Metastases
Oct 25, 2000
|
12.2 KB |
|
| |
Boston, MAOctober 25, 2000Company Also Reports Preliminary Results From Ongoing Phase I Trial of Xcytrin®
For Primary Brain Tumors
PRNewswire -- Pharmacyclics, Inc. (Nasdaq: PCYC)today
reported results from...
|
|
Pharmacyclics Announces Start of NCI-Sponsored Phase I Clinical Trials Of Xcytrin® in Primary Lung Cancer and With Stereotactic Radiosurgery For Advanced Brain Tumors
Sep 7, 2000
|
11.6 KB |
|
| |
Sunnyvale, CASeptember 7, 2000PRNewswire --
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the initiation of two Phase
I clinical trials with the company's Xcytrin® (motexafin gadolinium)
Injection. These studies, w...
|
|
Pharmacyclics Reports Fourth Quarter and Fiscal 2000 Financial Results
Aug 24, 2000
|
12.5 KB |
|
| |
Sunnyvale, CAAugust 24, 2000PRNewswire --
Pharmacyclics, Inc. (Nasdaq: PCYC), today reported financial results for its
fourth quarter and fiscal year ended June 30, 2000. For the fourth quarter,
the company reported a net l...
|
|
Clinical Investigators Expect to Complete Enrollment By End of 2000
Jul 24, 2000
|
12.2 KB |
|
| |
Sunnyvale, CAJuly 24, 2000PRNewswire -- Pharmacyclics, Inc.
(Nasdaq: PCYC), today reported on the progress of its ongoing randomized
controlled Phase III clinical trial of Xcytrin® (motexafin gadolinium)
Injection, for t...
|
|
Pharmacyclics Appoints Richard L. Levy to Board of Directors
Jun 8, 2000
|
8.6 KB |
|
| |
Sunnyvale, CAJune 8, 2000PRNewswire --
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the appointment of Richard
L. Levy, Ph.D., to its Board of Directors. The company also announced that
Joseph C. Scodari is leaving th...
|
|
Pharmacyclics Reports on Status of Ongoing Phase III Clinical Trial of Xcytrin® For Brain Metastases
May 22, 2000
|
11.9 KB |
|
| |
Sunnvale, CAMay 22, 2000Neurocognitive Lead-In Data Presented at ASCO Meeting
PRNewswire --
Pharmacyclics, Inc. (Nasdaq: PCYC) today reported on the progress of its
ongoing 425-patient randomized Phase III clinical tr...
|
|
Pharmacyclics Appoints Cynthia J. Ladd
May 4, 2000
|
8.1 KB |
|
| |
Sunnyvale, CAMay 4, 2000Senior Vice President and General Counsel
PRNewswire --
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the company has named
Cynthia J. Ladd Senior Vice President and General Counsel....
|
|
Pharmacyclics Reports Third Quarter Results
May 4, 2000
|
12.4 KB |
|
| |
Sunnyvale, CAMay 4, 2000PRNewswire --
Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its
third quarter ended March 31, 2000. The net loss for the period was
$7,251,000, or $0.47 per share, compared ...
|
|
Pharmacyclics Announces Preliminary Results From Ongoing Phase II DOSE-RANGING STUDY With Optrin™ for the Treatment of Age-Related Macular Degeneration
May 3, 2000
|
10.6 KB |
|
| |
Sunnyvale, CAMay 3, 2000Clinical Results Presented at ARVO Annual Meeting
PRNewswire -- Pharmacyclics (Nasdaq: PCYC)
today announced preliminary results from an ongoing Phase II dose-ranging
study with Optrin™...
|
|
Pharmacyclics Appoints Two New Board Members
Mar 2, 2000
|
9.3 KB |
|
| |
Sunnyvale, Ca. -- PRNewswireMarch 2, 2000
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the appointments of William
R. Rohn and Miles R. Gilburne to its Board of Directors. The company also
announced that Joseph S. La...
|
|
Pharmacyclics Announces $60 Million Private Placement
Mar 2, 2000
|
8.0 KB |
|
| |
Sunnyvale, CAMarch 2, 2000Pharmacyclics, Inc. (Nasdaq: PCYC), announced today that it has entered into
definitive purchase agreements for the sale of 820,000 shares of newly issued
common stock to selected institutional inves...
|
|
Pharmacyclics Announces Start of Phase I Clinical Trial of Antrin® Photoangioplasty for Coronary Artery Disease
Feb 29, 2000
|
10.8 KB |
|
| |
Sunnyvale, Ca. -- PRNewswireFebruary 29, 2000
Pharmacyclics, Inc. (Nasdaq: PCYC), announced the start of a Phase I clinical
trial of photoangioplasty with Antrin® (motexafin lutetium) Injection for
treatment of coronary...
|
|
Pharmacyclics Reports Second Quarter Results
Feb 3, 2000
|
13.5 KB |
|
| |
Sunnyvale, Ca. (PRNewswire)February 3, 2000
Pharmacyclics, Inc.
(Nasdaq: PCYC) today reported financial results for its second quarter ended
December 31, 1999. The net loss for the period was $5,407,000, or $0.36 per
share,...
|
|
Pharmacyclics Receives Milestone Payment From Alcon to Continue Development Of Optrin™ for Ophthalmology
Jan 10, 2000
|
10.3 KB |
|
| |
Sunnyvale, Ca. (PRNewswire)January 10, 2000
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that Alcon has committed to
continuing clinical development of Optrin™ (motexafin lutetium) Injection
in the field of ophthalmo...
|
|
Pharmacyclics Announces Start of Phase I Trial of Xcytrin® in Childhood Gliomas
Nov 19, 1999
|
13.2 KB |
|
| |
Sunnyvale, Ca. (PRNewswire)November 19, 1999
Pharmacyclics, Inc.
(Nasdaq: PCYC)
today announced the initiation of a Phase I clinical trial with
the company's Xcytrin® (motexafin gadolinium) Injection for treating
ch...
|
|
Pharmacyclics Announces Final Phase I Study Results Of Antrin® Photoangioplasty at AHA Meeting
Nov 10, 1999
|
11.8 KB |
|
| |
Atlanta, Ga. (PRNewswire)November 10, 1999New Preclinical Studies also Demonstrate Treatment Reduces Atherosclerosis by Eliminating Inflammatory Cells
Pharmacyclics, Inc. (Nasdaq: PCYC) today
announced that final r...
|
|
Pharmacyclics Announces Publication of Preclinical Data Supporting Xcytrin®'s Clinical Activity and Novel Mechanism of Action
Nov 5, 1999
|
10.6 KB |
|
| |
Sunnyvale, Ca. (PRNewswire)November 5, 1999
Pharmacyclics, Inc.
(Nasdaq: PCYC)
today announced the publication of preclinical study results of
Xcytrin® (motexafin gadolinium) Injection in the November issue of the
I...
|
|
|
